SCHEMBL6862938

SCHEMBL6862938

O=C(O)c1cccc(COc2cc(Cl)ccc2NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 10/20 0.63
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TP53 P04637 2/20 0.56
HPGD P15428 2/20 0.56
MITF O75030 1/20 0.56
XBP1 P17861 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
PTGER1 P34995 1/20 0.53
ALDH1A1 P00352 1/20 0.53
KDM4E B2RXH2 1/20 0.52
TSHR P16473 1/20 0.52
PTK2B Q14289 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861404 0.89 MRGPRX4 (0.56) MRGPRX4MEN1KMT2AHPGDPTGER1
SCHEMBL6862425 0.85 CCR2 (0.54) MRGPRX4CYP19A1
SCHEMBL6861108 0.84 MRGPRX4 (0.57) MRGPRX4ALDH1A1CYP19A1
SCHEMBL6860522 0.83 ERBB2 (0.48) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL8507796 0.81 MCL1 (0.56) PTGDR2SLC16A3
SCHEMBL6862302 0.81 CCR2 (0.59) MRGPRX4NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6861502 0.80 MCL1 (0.50) PTGDR2SLC16A3
SCHEMBL4502608 0.78 MRGPRX4 (1.00) MRGPRX4NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6863035 0.77 MRGPRX4 (0.55) MRGPRX4MEN1KMT2AHPGDPTGER1
SCHEMBL27490074 0.77 CCR2 (0.53) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN claimed
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US claimed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN claimed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP claimed
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN disclosed
US-6790866-B2 SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY ONO PHARMACEUTICAL CO., LTD. (JP) 2004-09-14 US disclosed
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US disclosed
US-6448290-B1 PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-10 US disclosed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN disclosed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity CNR1, HCAR1, HCAR2 MRGPRX4 361/4885NPC1 2634/4885RAB9A 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.